Dendritic cell based-immunotherapy after adjuvant chemotherapy in resectable PDAC
Clémence Toullec, Head and Neck Medical Oncologist at Cancer Institute Avignon Provence – Sainte Catherine, shared a paper by Freek R. van ‘t Land et al, on LinkedIn:
“Outstanding efficacy of dendritic cell based-immunotherapy after adjuvant chemotherapy completion in resectable PDAC recently published in JCO.
Recurrence free survival rate at 2 years 68% in this phase I/II trial. Remember : 2 years RFS was only 42% in the FOLFIRINOX arm in the PRODIGE24 trial.
The way to go for future trials design.”
Source: Clémence Toullec/LinkedIn
Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer
Authors: Freek R. van ‘t Land, Marcella Willemsen, Koen Bezemer, Sjoerd H. van der Burg, Thierry P.P. van den Bosch, Michail Doukas, Amine Fellah, P. Martijn Kolijn, Anton W. Langerak, Miranda Moskie, Elise van der Oost, Nina E.M. Rozendaal, Sara J. Baart, Joachim G.J.V. Aerts, and Casper H.J. van Eijck